Skip to main content
Neurotherapeutics logoLink to Neurotherapeutics
. 2007 Jan;4(1):62–69. doi: 10.1016/j.nurt.2006.11.013

Clinical development of antiepileptic drugs in adults

Bernd Schmidt 1,
PMCID: PMC7479699  PMID: 17199016

Summary

Over the last two decades, ten so-called newer antiepileptic drugs (AEDs) have been approved around the world, the majority of which have found and maintained a place in the seizure-fighting armamentarium for the whole spectrum of epilepsies and epileptic syndromes; some of these drugs have features that are improved compared with the older drugs. Within that same time period, the process of clinical development of AEDs has also undergone changes and has become much more complex and costly. Efforts are underway to shift decision-making about the clinical viability of AED candidates to earlier development stages, using the concept of translational medicine. However, thus far all of the newer AEDs have undergone a standard development as an adjunct in the control of adult partial seizures; in some cases, development has been expanded to other seizure types and pediatric syndromes. Currently, the path to global approval for use in monotherapy is under review and is often debated with regulatory authorities. Clinical treatment guidelines consider randomized, blinded, well controlled studies as the premier level of evidence-based medicine; these studies originate mostly in confirmatory phases of the development program. However, with the rigid designs and criteria in regulatory driven trials, effectiveness in the clinical practice setting may not be sufficiently predicted by these studies, leading to frustrations from individual practitioners. Finally, additional safety issues regularly occur only after the postlaunch exposure to a broader population making necessary a continuing, and thorough, pharmacovigilance after the AED has come to market.

Key Words: Antiepileptic drugs (AED), clinical trials, adjunctive trials, monotherapy, AED development

References

  • 1.Katz R. FDA update. Epilepsy Res. 2006;68:85–94. doi: 10.1016/j.eplepsyres.2005.09.034. [DOI] [PubMed] [Google Scholar]
  • 2.White S. Preclinical development of antiepileptic drugs: past, present and future directions. Epilepsia. 2003;44(suppl 7):2–8. doi: 10.1046/j.1528-1157.44.s7.10.x. [DOI] [PubMed] [Google Scholar]
  • 3.Bickerstaffe R, Brock P, Husson J-M, et al. Ethics and pharmaceutical medicine. Int J Clin Pract. 2006;60:242–252. doi: 10.1111/j.1742-1241.2006.00804.x. [DOI] [PubMed] [Google Scholar]
  • 4.Schmidt B. Gabapentin. In: Levy R, Mattson R, Meldrum B, Penry I, Dreifuss FE, editors. Antiepileptic drugs. 3rd ed. New York: Raven Press; 1989. [Google Scholar]
  • 5.Wolf P, Schmidt B. Early phase II testing of ralitoline. Excerpta Medica 1988:ISBN 444-01365-2:45–56.
  • 6.Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia. 1994;35:113–121. doi: 10.1111/j.1528-1157.1994.tb02920.x. [DOI] [PubMed] [Google Scholar]
  • 7.Gabapentin in partial epilepsy. UK Gabapentin Study Group Lancet. 1990;335:1114–1117. [PubMed] [Google Scholar]
  • 8.Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5. Neurology 1993;43:2292–2298. [DOI] [PubMed]
  • 9.Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52:1882–1887. doi: 10.1212/wnl.52.9.1882. [DOI] [PubMed] [Google Scholar]
  • 10.Littman BH, Williams SA. The ultimate model organism: progress in experimental medicine. Nat Rev Drug Discov. 2005;4:631–638. doi: 10.1038/nrd1800. [DOI] [PubMed] [Google Scholar]
  • 11.Katz R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx. 2004;l:189–195. doi: 10.1602/neurorx.1.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Schmidt B. Roof of principle studies. Epilepsy Res. 2006;68:48–52. doi: 10.1016/j.eplepsyres.2005.09.019. [DOI] [PubMed] [Google Scholar]
  • 13.Schmidt B. How to avoid misinterpreting results of clinical trials. Epilepsia. 2005;46(suppl 6):18–18. [Google Scholar]
  • 14.Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000;14:301–319. doi: 10.1111/j.1472-8206.2000.tb00411.x. [DOI] [PubMed] [Google Scholar]
  • 15.Bumeo JG, Montori VM, Faught E. Placebo effect in antiepileptic drug trials. Epilepsy Behav. 2003;4:371–371. doi: 10.1016/S1525-5050(03)00112-4. [DOI] [PubMed] [Google Scholar]
  • 16.Pledger GW, Sahlroot JT. Alternative analyses for antiepileptic drug trials. Epilepsy Res Suppl. 1993;10:167–174. [PubMed] [Google Scholar]
  • 17.Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597–1607. doi: 10.1111/j.1499-1654.2000.001597.x. [DOI] [PubMed] [Google Scholar]
  • 18.Schmidt B. Randomized monotherapy trials of new anti-epileptic drugs. Can “evidence-based medicine” be misleading? Epilepsia. 2002;43(suppl 8):21–22. [Google Scholar]
  • 19.Baker GA, Currie NJ, Light MJ, et al. The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy — a Canadian study. Scizure. 2002;11:6–15. doi: 10.1053/seiz.2001.0581. [DOI] [PubMed] [Google Scholar]
  • 20.Ben-Menachem E, Edrich P, Van Vleyman B, Sander JWAS, Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res. 2003;53:57–64. doi: 10.1016/S0920-1211(02)00247-4. [DOI] [PubMed] [Google Scholar]
  • 21.Wong ICK, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf. 2000;23:35–56. doi: 10.2165/00002018-200023010-00003. [DOI] [PubMed] [Google Scholar]
  • 22.French JA, Schachter S. A Workshop on AED monotherapy. Epilepsia. 2002;43(suppl 10):3–27. doi: 10.1046/j.1528-1157.43.s.10.1.x. [DOI] [PubMed] [Google Scholar]
  • 23.Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology. 1997;49:746–752. doi: 10.1212/wnl.49.3.746. [DOI] [PubMed] [Google Scholar]
  • 24.Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Neurology. 1997;49:739–745. doi: 10.1212/wnl.49.3.739. [DOI] [PubMed] [Google Scholar]
  • 25.Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52:732–737. doi: 10.1212/wnl.52.4.732. [DOI] [PubMed] [Google Scholar]
  • 26.Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand. 2005;112:214–222. doi: 10.1111/j.1600-0404.2005.00485.x. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES